GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaresearch Bio Co Ltd (XKRX:217950) » Definitions » NonCurrent Deferred Liabilities

Pharmaresearch Bio Co (XKRX:217950) NonCurrent Deferred Liabilities : ₩0 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Pharmaresearch Bio Co NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Pharmaresearch Bio Co's non-current deferred liabilities for the quarter that ended in Dec. 2023 was ₩0 Mil.

Pharmaresearch Bio Co NonCurrent Deferred Liabilities Historical Data

The historical data trend for Pharmaresearch Bio Co's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaresearch Bio Co NonCurrent Deferred Liabilities Chart

Pharmaresearch Bio Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial - - - - -

Pharmaresearch Bio Co Semi-Annual Data
Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
NonCurrent Deferred Liabilities Get a 7-Day Free Trial - - - - -

Pharmaresearch Bio Co NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Pharmaresearch Bio Co's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmaresearch Bio Co Business Description

Traded in Other Exchanges
N/A
Address
641-3, Saimdang-ro, Gangwon-do, Gangneung-si, KOR, 13494
Pharmaresearch Bio Co Ltd is a Korea-based biopharmaceutical company. The company is engaged in the research and development, manufacturing, sale, and marketing of biopharmaceutical products. Its product is ReNTox Injections, and Clostridium Botulinum Toxin type A is in pipeline.

Pharmaresearch Bio Co Headlines

No Headlines